18 June 1993 Photodynamic diagnosis following intravesical instillation of aminolevulinic acid (ALA): first clinical experiences in urology
Author Affiliations +
Proceedings Volume 1881, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy II; (1993) https://doi.org/10.1117/12.146310
Event: OE/LASE'93: Optics, Electro-Optics, and Laser Applications in Scienceand Engineering, 1993, Los Angeles, CA, United States
Abstract
Delta Aminolevulinic acid (ALA), a precursor of Protoporphyrin IX (PP IX) in hem biosynthesis has been topically applied in urinary bladders in order to study its potential as fluorescent tumor marker. Preclinical experiments have been performed on chemically induced tumors in rats, revealing a ratio of PP IX-fluorescence intensity up to 20:1 in tumors as compared to healthy urothelium. Synthesis of PP IX has been stimulated in 56 patients by intravesical instillation of a pH-neutral ALA-solution. After an incubation time of two to four hours strong red fluorescence was endoscopically observed even in tiny superficial tumors. Brightness and contrast allows visualization of early stage urothelial diseases with naked eyes and without the necessity suppressing background fluorescence or violet excitation light.
© (1993) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Reinhold Baumgartner, Reinhold Baumgartner, M. Kriegmair, M. Kriegmair, Herbert G. Stepp, Herbert G. Stepp, W. Lumper, W. Lumper, Peter Heil, Peter Heil, Rainer Riesenberg, Rainer Riesenberg, Susanne Stocker, Susanne Stocker, Alfons G. Hofstetter, Alfons G. Hofstetter, } "Photodynamic diagnosis following intravesical instillation of aminolevulinic acid (ALA): first clinical experiences in urology", Proc. SPIE 1881, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy II, (18 June 1993); doi: 10.1117/12.146310; https://doi.org/10.1117/12.146310
PROCEEDINGS
6 PAGES


SHARE
Back to Top